Beacon Biosignals

Stub active Updated Apr 7, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Boston, Massachusetts
Founded 2019
Latest Stage Series B
Total Raised $132M
Website https://beacon.bio
Sector
healthtech neurotechnology ai

Investors

General Catalyst series-b (2026)
GV (Google Ventures) series-b (2026)

Founders

Jacob Donoghue Co-Founder & CEO
Jarrett Revels Co-Founder
Sydney Cash Co-Founder
Brandon Westover Co-Founder

About

Beacon Biosignals is a Boston, Massachusetts-based neurotechnology company founded in 2019 1. The company combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine 1. Co-founded by Jacob Donoghue (CEO), Jarrett Revels, Sydney Cash, and Brandon Westover, the company upsized its Series B financing to over $97 million in April 2026, bringing cumulative funding to over $132 million 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-06 Series B (extension) $97.2M Innoviva, GV, S32, Catalio Capital, General Catalyst Logos Capital, Casdin Capital, Indicator Ventures, JSL Health, Palo Santo VC, Kicker Ventures, Samsung Next 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

Jacob Donoghue (CEO): “This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable.” 1

Sources

  1. GlobeNewsWire, “Beacon Biosignals Upsizes Series B Financing to Over $97 Million,” April 6, 2026. https://www.globenewswire.com/news-release/2026/04/06/3268317/0/en/Beacon-Biosignals-Upsizes-Series-B-Financing-to-Over-97-Million.html↩↩↩↩↩